Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 3 of 15

 
 

Dr. Reddy's Laboratories (NYSE:RDY)

Consensus Rating
Hold
Rating Score
2.0
Ratings Breakdown
1 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$81.00 (16.5% Upside)

About Dr. Reddy's Laboratories

Dr. ReddyDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
5/8/2024BarclaysBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $81.00
1/29/2024BarclaysBoost Price TargetOverweight ➝ Overweight$75.00 ➝ $80.00
1/11/2024Jefferies Financial GroupDowngradeBuy ➝ Underperform
8/29/2023HSBCDowngradeBuy ➝ Hold
6/1/2023BarclaysBoost Price Target$67.00 ➝ $70.00
5/18/2023Sanford C. BernsteinDowngradeOutperform ➝ Market Perform
3/17/2023Bank of AmericaUpgradeNeutral ➝ Buy
1/30/2023JPMorgan Chase & Co.Initiated CoverageUnderweight
11/14/2022Credit Suisse GroupDowngradeNeutral ➝ Underperform
10/31/2022BarclaysBoost Price TargetOverweight$66.00 ➝ $67.00
 

Digitizing the $11T commodities sector with one tiny stock (Ad)

One tiny company — trading completely undiscovered around 15-cents per share — has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector.

It’s an opportunity that likely won’t stay at these levels for long